{"analyses":[{"ciLowerLimit":"0.58","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.16","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.7280","paramType":"Odds Ratio (OR)","paramValue":"1.12","statisticalMethod":"Regression, Logistic"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.7","upperLimit":"35.6","value":"27.1"},{"groupId":"OG001","lowerLimit":"19.6","upperLimit":"38.2","value":"28.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"96"}],"units":"Participants"}],"description":"Percentage of participants who die or require non-invasive ventilation or invasive mechanical ventilation, including ECMO.","dispersionType":"95% Confidence Interval","groups":[{"description":"Placebo administered orally QD with standard of care.","id":"OG000","title":"Placebo + SOC"},{"description":"4 mg baricitinib administered orally QD with standard of care.","id":"OG001","title":"Baricitinib + SOC"}],"paramType":"NUMBER","populationDescription":"All participants randomly assigned to study intervention who at baseline required oxygen supplementation and did not receive dexamethasone, or other systemic corticosteroids for the primary study condition.","reportingStatus":"POSTED","timeFrame":"Day 1 to Day 28","title":"Percentage of Participants Who Die or Require Non-Invasive Ventilation/High-Flow Oxygen or Invasive Mechanical Ventilation (Including Extracorporeal Membrane Oxygenation [ECMO] Population 2","type":"PRIMARY","unitOfMeasure":"percentage of participants"}